Hoopes Richard R, Raja Khalid M, Koich April, Hueber Paul, Reid Robert, Knohl Stephen J, Scheinman Steven J
Department of Medicine, State University of New York Upstate Medical University, Syracuse, New York 13210, USA.
Kidney Int. 2004 May;65(5):1615-20. doi: 10.1111/j.1523-1755.2004.00571.x.
Dent's disease (X-linked nephrolithiasis) is a proximal tubulopathy that has been consistently associated with inactivating mutations in the CLCN5 gene encoding the ClC-5 chloride channel expressed in tubular epithelial cells.
We performed mutation analysis of the coding region of CLCN5 by DNA sequencing in 32 unrelated males, all of whom met the following three clinical criteria for the diagnosis of Dent's disease: (1) low-molecular-weight (LMW) proteinuria; (2) hypercalciuria; and (3) at least one of the following: nephrocalcinosis, kidney stones, renal insufficiency, hypophosphatemia, or hematuria.
Sixteen mutations (ten missense, four nonsense, two frameshift) were found in 19 patients. Mutations were confirmed by restriction analysis or allele-specific polymerase chain reaction (PCR), segregated with disease in the families, and were not polymorphisms. In the other 13 patients with Dent's disease, the coding sequence of CLCN5 was normal. In these 13 patients, we also sequenced two regions of the CLCN5 promoter (626 and 586 bp, respectively, 2.1 and 1 kb upstream of exon 2) containing regulatory sites [activating protein-1 (AP-1)-like, AP-4, and cyclic adenosine monophosphate (cAMP)-receptor element binding protein (CREB)] and primary and secondary transcription start sites. We found no mutations in these promoter sequences in any of the 13 patients. In one three-generation family, the absence of mutation was confirmed by sequencing in two additional affected family members, and in this family haplotype analysis excluded linkage to the region of the CLCN5 gene. There were no differences between the 19 patients with CLCN5 mutations and the 13 without mutations with regard to any clinical features of Dent's disease.
These findings suggest that mutation in other gene(s) may be responsible for the phenotype of Dent's disease in some patients.
丹特病(X连锁肾结石病)是一种近端肾小管病,一直与编码肾小管上皮细胞中表达的ClC-5氯通道的CLCN5基因的失活突变相关。
我们对32名无亲缘关系的男性进行了DNA测序,以分析CLCN5编码区的突变情况,所有这些男性均符合丹特病诊断的以下三项临床标准:(1)低分子量(LMW)蛋白尿;(2)高钙尿症;(3)以下至少一项:肾钙质沉着症、肾结石、肾功能不全、低磷血症或血尿。
在19名患者中发现了16种突变(10种错义突变、4种无义突变、2种移码突变)。通过限制性分析或等位基因特异性聚合酶链反应(PCR)对突变进行了确认,在家族中与疾病共分离,且不是多态性。在其他13名丹特病患者中,CLCN5的编码序列正常。在这13名患者中,我们还对CLCN5启动子的两个区域(分别为626和586 bp,位于外显子2上游2.1和1 kb处)进行了测序,这些区域包含调控位点[激活蛋白-1(AP-1)样、AP-4和环磷酸腺苷(cAMP)反应元件结合蛋白(CREB)]以及初级和次级转录起始位点。我们在这13名患者中的任何一人的这些启动子序列中均未发现突变。在一个三代家族中,通过对另外两名受影响家族成员的测序确认了无突变情况,并且在这个家族中,单倍型分析排除了与CLCN5基因区域的连锁关系。在丹特病的任何临床特征方面,19名有CLCN5突变的患者与13名无突变的患者之间没有差异。
这些发现表明,其他基因的突变可能是某些患者丹特病表型的原因。